An Analysis of the Risk Factors for New-Onset Diabetes Mellitus After Liver Transplantation

References

• Samuel D, Coilly A. Management of patients with liver diseases on the waiting list for transplantation: a major impact to the success of liver transplantation. BMC Med. 2018;16(1):113. doi:10.1186/s12916-018-1110-y
   PubMed Web of Science ®Google Scholar
• Ahn HY, Cho YM, Yi NJ. Predictive factors associated with the reversibility of post-transplantation diabetes mellitus following liver transplantation. J Korean Med Sci. 2009;24(4):567–570. doi:10.3346/jkms.2009.24.4.567
   PubMed Web of Science ®Google Scholar
• Midtvedt K, Hjelmesaeth J, Hartmann A, et al. Insulin resistance after renal transplantation: the effect of steroid dose reduction and withdrawal. Am Soc Nephrol. 2003;15:3233–3239. doi:10.1097/01.ASN.0000145435.80005.1E
   Web of Science ®Google Scholar
• Hur KY, Kim MS, Kim YS, et al. Risk factor associated with the onset and progression of post transplantation diabetes in renal allograft recipients. Diabetes Care. 2007;19:136–143.
   Google Scholar
• Jenssen T, Hartmann A. Post-transplant diabetes mellitus in patients with solid organ transplants. Nat Rev Endocrinol. 2019;15(3):172–188. doi:10.1038/s41574-018-0137-7
   PubMed Web of Science ®Google Scholar
• Chen Z, Li YX, Fu HJ, et al. Hepatitis B virus core antigen stimulates IL-6 expression via p38, ERK and NF-κB pathways in hepatocytes. Cell Physiol Biochem. 2017;41(1):91–100. doi:10.1159/000455954
   PubMedGoogle Scholar
• Luo HB, Xia W, Cao HT, et al. Expression and clinical significance of T cell subsets, IL-6 and IL-8 levels in peripheral blood of patients with hepatitis B. Prog Mod Biomed. 2018;18(7):2517–2521.
   Google Scholar
• Chen CF, Leu FJ, Chen HI, et al. Lack of a protective effect of insulin on three reperfusion-liver injury models in rats and mice. Transplant Proc. 2006;38(7):2221–2225. doi:10.1016/j.transproceed.2006.07.016
   PubMed Web of Science ®Google Scholar
• Rehman K, Akash MSH, Liaqat A, Kamal S, Qadir MI, Rasul A. Role of interleukin-6 in development of insulin resistance and type 2 diabetes mellitus. Crit Rev Eukaryot Gene Expr. 2017;27(3):229–236. doi:10.1615/CritRevEukaryotGeneExpr.2017019712
   PubMed Web of Science ®Google Scholar
• Kim KE, Heo JS, Han S, et al. Blood concentrations of lipopolysaccharide-binding protein, high-sensitivity C-reactive protein, tumor necrosis factor-α, and interleukin-6 in relation to insulin resistance in young adolescents. Clin Chim Acta. 2018;486:115–121. doi:10.1016/j.cca.2018.07.042
   PubMed Web of Science ®Google Scholar
• Rotter V, Nagaev I, Smith U. Interleukin.6(IL.6) induces insulin resistance in 333-L1 adipocytes and is, like IL-8 and tumor necrosis factor-alpha, over expressed in human fat cells from insulin-resistant subjects. J Biol Chem. 2003;278(46):45777–45784. doi:10.1074/jbc.M301977200
   PubMed Web of Science ®Google Scholar
• Fève B, Bastard JP. The role of interleukins in insulin resistance and type 2 diabetes mellitus. Nat Rev Endocrinol. 2009;5(6):305–311. doi:10.1038/nrendo.2009.62
   PubMed Web of Science ®Google Scholar
• Fasshauer M, Kralisch S, Klier M, et al. Adiponectin gene expression and secretion is inhibited by interleukin-6 in 3T3-L1 adipocytes. Biochem Biophys Res Commun. 2003;301(4):1045–1050. doi:10.1016/S0006-291X(03)00090-1
   PubMed Web of Science ®Google Scholar
• Kanemaki T, Kitade H, Kaibori M, et al. Interleukin 1β and interleukin 6, but not tumor necrosis factor α, inhibit insulin‐stimulated glycogen synthesis in rat hepatocytes. Hepatology. 1998;11(27):1296–1303. doi:10.1002/hep.510270515
   Web of Science ®Google Scholar
• Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA. 2001;2863(3):327–334. doi:10.1001/jama.286.3.327
   Web of Science ®Google Scholar
• Bastard J-P, Maachi M, Lagathu C, et al. Recent advances in the relationship between obesity, inflammation, and insulin resistance. Eur Cytokine Netw. 2006;17(1):4–12.
   PubMed Web of Science ®Google Scholar
• Kuo H-T, Sampaio MS, Ye X, et al. Risk factors for new-onset diabetes mellitus in adult liver transplant recipients, an analysis of the organ procurement and transplant network/united network for organ sharing database. Transplantation. 2010;89(9):1134. doi:10.1097/TP.0b013e3181d2fec1
   PubMed Web of Science ®Google Scholar
• Zheng J, Wang WL. Risk factors of metabolic syndrome after liver transplantation. Hepatobiliary Pancreat Dis Int. 2015;14(6):582–587. doi:10.1016/S1499-3872(15)60037-6
   PubMed Web of Science ®Google Scholar
• Orsi E, Grancini V, Menini S, Aghemo A, Pugliese G. Hepatogenous diabetes: is it time to separate it from type 2 diabetes? Liver Int. 2017;37(7):950–962. doi:10.1111/liv.13337
   PubMed Web of Science ®Google Scholar
• Hui JM, Sud A, Farrell GC, et al. Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression. Gastroenterology. 2003;125:1695–1704. doi:10.1053/j.gastro.2003.08.032
   PubMed Web of Science ®Google Scholar
• Grancini V, Trombetta M, Lunati ME, et al. Central role of the beta-cell in driving regression of diabetes after liver transplantation in cirrhotic patients. J Hepatol. 2019;5(70):954–962. doi:10.1016/j.jhep.2019.01.015
   Web of Science ®Google Scholar
• Li DW, Lu TF, Hua XW, et al. Risk factors for new onset diabetes mellitus after liver transplantation: a meta-analysis. World J Gastroenterol. 2015;21(20):6329–6340. doi:10.3748/wjg.v21.i20.6329
   PubMed Web of Science ®Google Scholar
• Hartog H, May CJ, Corbett C, et al. Early occurrence of new-onset diabetes after transplantation is related to type of liver graft and warm ischaemic injury. Liver Int. 2015;35(6):1739–1747. doi:10.1111/liv.12706
   PubMed Web of Science ®Google Scholar
• Ilmakunnas M, Tukiainen EM, Rouhiainen A, et al. High mobility group box 1 protein as a marker of hepatocellular injury in human liver transplantation. Liver Transpl. 2008;14(10):1517–1525. doi:10.1002/lt.21573
   PubMed Web of Science ®Google Scholar
• Huebener P, Pradere JP, Hernandez C, et al. The HMGB1/RAGE axis triggers neutrophil-mediated injury amplification following necrosis. J Clin Invest. 2015;125(2):539–550. doi:10.1172/JCI76887
   PubMed Web of Science ®Google Scholar
• Pahwa R, Jialal I. The role of the high-mobility group box1 protein-toll like receptor pathway in diabetic vascular disease. J Diabetes Complications. 2016;30(6):1–6. doi:10.1016/j.jdiacomp.2016.03.005
   PubMed Web of Science ®Google Scholar
• Hryniewiecka E, Zegarska J, Paczek L. Arterial hypertension in liver transplant recipients. Transplant Proc. 2011;43(8):3029–3034. doi:10.1016/j.transproceed.2011.07.011
   PubMed Web of Science ®Google Scholar
• Ling Q, Xu X, Xie H, et al. New-onset diabetes after liver transplantation: a national report from China liver transplant registry. Liver Int. 2016;36(5):705–712. doi:10.1111/liv.13042
   PubMed Web of Science ®Google Scholar
• Yagi S, Kaido T, Iida T, et al. New-onset diabetes mellitus after living-donor liver transplantation: association with graft synthetic function. Surg Today. 2017;47:733–742. doi:10.1007/s00595-016-1444-z
   PubMed Web of Science ®Google Scholar
• Rodriguez‐Rodriguez AE, Donate-Correa J, Rovira J, et al. Inhibition of the mTOR pathway: a new mechanism of β cell toxicity induced by tacrolimus. Am J Transplant. 2019;4(19):3240–3249. doi:10.1111/ajt.15483
   Web of Science ®Google Scholar
• Rostaing L, Bunnapradist S, Grinyó JM, et al. Novel once-daily extended-release tacrolimus versus twice-daily tacrolimus in de novo kidney transplant recipients: two-year results of phase 3, double-blind, randomized trial. Am J Kidney Dis. 2016;67(4):648–659. doi:10.1053/j.ajkd.2015.10.024
   PubMed Web of Science ®Google Scholar
• Grancini V, Resi V, Palmieri E, Pugliese G, Orsi E. Management of diabetes mellitus in patients undergoing liver transplantation. Pharmacol Res. 2019;1(141):556–573. doi:10.1016/j.phrs.2019.01.042
   Web of Science ®Google Scholar
• Yadav AD, Chang YH, Aqel BA, et al. New onset diabetes mellitus in living donor versus deceased donor liver transplant recipients: analysis of the UNOS/OPTN database. J Transplant. 2013;2013:269096. doi:10.1155/2013/269096
   PubMedGoogle Scholar
• Ling Q, Xie H, Lu D, et al. Association between donor and recipient TCF7L2 gene polymorphisms and the risk of new-onset diabetes mellitus after liver transplantation in a Han Chinese population. J Hepatol. 2013;58(2):271–277. doi:10.1016/j.jhep.2012.09.025
   PubMed Web of Science ®Google Scholar